Rothschild Redburn raises target for Abbott Laboratories stock to USD 127
Published on 10/14/2026 at 10:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst upgrade and product execution
- Rothschild Redburn raised its Abbott target to USD 127 from USD 119 on October 2, 2026.
- Abbott began U.S. commercialization of SimpleScreen CRC on October 13, 2026.
- Abbott Laboratories stock trades at EUR 91.37 at 10:45 a.m. CEST at Lang & Schwarz on October 14, 2026.
Abbott Laboratories (ISIN US0028241000) was trading at EUR 91.37 at Lang & Schwarz on October 14, 2026 at 10:45 a.m. CEST. On October 2, 2026, Rothschild Redburn upgraded Abbott from Neutral to Buy and raised its target from USD 119 to USD 127, as Investing.com reported.
Redburn points to device growth
The analyst view centers on Abbott's Medical Devices business, which Rothschild Redburn expected to grow 10.60 percent organically in fiscal 2026. The firm also projected 11.70 percent growth for Abbott's diabetes technology segment in fiscal 2026, while citing cardiovascular products and diabetes operations as additional support.
The same analysis linked the outlook to Abbott's acquisition of Exact Sciences and to the Cologuard franchise. It also identified pressure from the Nutrition business and legal costs as factors that could delay margin improvement, giving the target increase a clear execution condition.
Results date brings a measurable test
Abbott is scheduled to release third-quarter 2026 results before the market opens on October 21, 2026, according to MarketBeat. The consensus cited by the outlet calls for earnings of USD 1.42 per share and revenue of USD 13.00 billion, while Abbott's third-quarter earnings guidance stands at USD 1.38-1.46 per share.
In the second quarter of 2026, Abbott reported revenue of USD 12.59 billion, up 13.00 percent year over year, and net income of USD 928.00 million. The company also raised full-year adjusted earnings-per-share guidance to USD 5.45-5.60, according to Investing.com.
Diagnostics adds a second growth lane
Abbott began U.S. commercialization of the FDA-approved SimpleScreen CRC blood-based colorectal cancer screening test, alongside recent developments in nutrition and heart-failure monitoring, on October 13, 2026, as Simply Wall St reported. That product broadens Abbott's diagnostics portfolio, but the October 21 results will provide the next quantified test of demand and margin execution.
Price and reporting date
Abbott Laboratories stock was trading at EUR 91.37 at Lang & Schwarz on October 14, 2026 at 10:45 a.m. CEST. The company has a market capitalization of USD 177.7 billion, and the NYSE listing uses ticker ABT.
The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.
Abbott Laboratories stock facts
- Company: Abbott Laboratories
- ISIN: US0028241000
- Ticker: ABT
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 14, 2026, 10:45 a.m. CEST): EUR 91.37
- Market capitalization: USD 177.7 billion (as of October 14, 2026)
- Sector / Industry: Health Care / Medical Equipment
Market context: Market report S&P 500.
